시장보고서

상품코드

1750733

자가면역질환 진단 시장 규모, 점유율, 동향 분석 보고서 : 유형별, 제품 유형별, 검사 유형별, 최종 용도별, 지역별, 부문별 예측(2025-2030년)

Autoimmune Disease Diagnostics Market Size, Share & Trends Analysis Report By Type (Systemic Autoimmune Disease Diagnostics, Localized Autoimmune Disease Diagnostics), By Product, By Test Type, By End Use, By Region, And Segment Forecasts, 2025 - 2030

발행일: 2025년 05월 | 리서치사:

Grand View Research | 페이지 정보: 영문 129 Pages | 배송안내 : 2-10일 (영업일 기준)

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

자가면역질환 진단 시장 성장과 동향:

Grand View Research, Inc.의 최신 보고서에 따르면, 세계 자가면역질환 진단 시장 규모는 2025년부터 2030년까지 연평균 6.18%의 CAGR로 확대되어 2030년에는 82억 달러에 달할 것으로 추정됩니다. 정부 기관 및 관련 단체들은 이러한 고가의 의료비를 억제하는 동시에 환자들에게 개선된 진단 및 치료 솔루션을 제공하기 위해 노력하고 있습니다. 그 결과, NIH의 자가면역질환 관련 연구개발 프로그램에 대한 자금 지원이 증가하고 있습니다.

또한, 이러한 질병의 발생을 억제하고 실행 가능한 진단 및 치료 옵션을 개발하는 것을 목표로 하는 정부의 호의적인 이니셔티브의 존재는 예측 기간 동안 시장 성장을 촉진할 것으로 예상됩니다.

자가면역진단 시술이 증가함에 따라 보다 빠르고 효과적인 결과를 제공하는 장비와 시설에 대한 요구가 증가하고 있습니다. 늘어나는 시술량에 대응하기 위해 진단 검사실은 빠르게 자동화를 향해 나아가고 있습니다. 실험실 자동화는 빠른 처리 시간으로 업무 부담을 줄이고, 표준화되고 반복 가능한 결과를 생성할 수 있도록 도와줍니다.

자가면역질환 진단 시장 보고서 하이라이트

국소 자가면역질환 진단 분야가 시장을 독점하고 2024년 매출 점유율 64.25%를 차지했습니다.
소모품 및 분석 부문은 2024년 70.43%의 가장 큰 매출 점유율을 차지했습니다. 모든 임상 검사 진단 테스트는 테스트 키트, 시약, 항체를 이용합니다.
검사 유형별로는 항핵항체 검사가 2024년 42.62%의 매출 점유율로 시장을 장악했습니다. 이 부문의 성장은 저렴한 가격, 높은 민감도, 풍부한 가용성 때문입니다.
병원 부문은 2024년 53.32%의 매출 점유율로 시장을 장악했습니다. 이러한 높은 점유율은 다양한 질병에 대한 병원에서 자가 면역 질환 진단의 채택이 증가하고 있기 때문입니다.
북미 자가면역질환 진단 시장은 2024년 매출 점유율 42.70%로 세계 시장을 지배했습니다. 아시아태평양의 자가면역질환 진단 시장은 2024년부터 2030년까지 가장 빠른 CAGR을 기록할 것으로 예상됩니다.

자가면역질환 진단 시장 : 유형별 변동 분석
전신성 자가면역질환 진단
- 전신성 자가면역질환 진단 시장, 2018-2030년
- 류마티스 관절염 진단
- 강직성 척추염 진단
- 전신홍반루푸스(SLE) 진단
- 기타 전신성 자가면역질환 진단
국소 질환 진단
- 국소적 질환 진단 시장, 2018-2030년
- 다발성 경화증 진단
- 1형 당뇨병 진단
- 하시모토병성 갑상선염 진단
- 특발성 혈소판 감소성 자반증(ITP) 진단
- 기타 국소적 자가면역질환 진단

제5장 제품 유형별 비즈니스 분석

자가면역질환 진단 시장 : 제품 유형별 변동 분석
기기
소모품과 어세이

제6장 검사 유형별 비즈니스 분석

자가면역질환 진단 시장 : 검사 유형별 변동 분석
항핵항체 검사
자가항체 검사
C 반응성 단백질(CRP)
전혈구수(CBC)
소변 검사
기타

제7장 최종 용도별 비즈니스 분석

자가면역질환 진단 시장 : 최종 용도별 변동 분석
병원
진단 센터
기타

제8장 지역별 비즈니스 분석

자가면역질환 진단 시장 점유율 : 지역별, 2024년 및 2030년
북미
- SWOT 분석
- 북미의 자가면역질환 진단 시장, 2018-2030년
- 미국
- 캐나다
- 멕시코
유럽
- SWOT 분석
- 유럽 자가면역질환 진단 시장, 2018-2030년
- 영국
- 독일
- 프랑스
- 이탈리아
- 스페인
- 영국
- 스웨덴
- 노르웨이
- 덴마크
아시아태평양
- SWOT 분석
- 아시아태평양의 자가면역질환 진단 시장, 2018-2030년
- 일본
- 중국
- 인도
- 호주
- 태국
- 한국
라틴아메리카
- SWOT 분석
- 라틴아메리카의 자가면역질환 진단 시장, 2018-2030년
- 브라질
- 아르헨티나
중동 및 아프리카
- SWOT 분석
- 중동 및 아프리카의 자가면역질환 진단 시장, 2018-2030년
- 남아프리카공화국
- 사우디아라비아
- 아랍에미리트
- 쿠웨이트

제9장 경쟁 구도

기업 분류
전략 매핑
기업 시장 점유율 분석, 2024년
기업 개요/상장 기업
- F. Hoffmann-La Roche Ltd
- Siemens Healthcare Private Limited
- Abbott
- Beckman Coulter, Inc.
- Danaher Corporation
- Quest Diagnostics
- EUROIMMUN Medizinische Labordiagnostika AG
- Nova Diagnostics Pte Ltd.
- BIOMERIEUX
- Hemagen Diagnostics, Inc.

ksm 25.06.27

Autoimmune Disease Diagnostics Market Growth & Trends:

The global autoimmune disease diagnostics market size is estimated to reach USD 8.20 billion by 2030, expanding at a CAGR of 6.18% from 2025 to 2030, according to a new report by Grand View Research, Inc. Government organizations along with related associations strive to curb such high healthcare costs and simultaneously provide improved diagnostic and therapeutic solutions to the patients. This has resulted in increased funding by the NIH for R&D programs related to autoimmune diseases.

Moreover, the presence of favorable government initiatives aimed at curbing the incidence of these diseases and developing viable diagnostic & treatment options is expected to drive market growth over the forecast period.

Growing volume of autoimmune diagnostic procedures has heightened the need for instruments and facilities rendering faster and effective results. In an attempt to cater to ever-increasing procedure volumes, diagnostic laboratories are rapidly moving toward automation. Lab automation helps decrease workload via rapid turnaround times and helps generate standardized & reproducible results.

Autoimmune Disease Diagnostics Market Report Highlights:

The localized autoimmune disease diagnostics segment dominated the market and accounted for a revenue share of 64.25% in 2024.
The consumables & assays segment accounted for the largest revenue share of 70.43% in 2024. Every laboratory diagnostic test utilizes test kits, reagents, and antibodies.
In terms of test type, the antinuclear antibody tests dominated the market with a revenue share of 42.62% in 2024. The growth of this segment is attributed to affordability, high sensitivity, and extensive availability.
The hospital segment dominated the market in 2024 with a revenue share of 53.32%. The high share is attributed to the increased adoption of autoimmune disease diagnostic practices in hospitals for various diseases.
The North America autoimmune disease diagnostics market dominated the global industry and accounted for a revenue share of 42.70% in 2024. The Asia Pacific autoimmune disease diagnostics market is anticipated to witness a fastest CAGR from 2024 to 2030.

Chapter 1. Methodology and Scope

1.1. Market Segmentation and Scope
- 1.1.1. Segment Definitions
  - 1.1.1.1. Type segment
  - 1.1.1.2. Product segment
  - 1.1.1.3. Test Type segment
  - 1.1.1.4. End use segment
1.2. Regional Scope
1.3. Estimates and Forecast Timeline
1.4. Objectives
- 1.4.1. Objective - 1
- 1.4.2. Objective - 2
- 1.4.3. Objective - 3
1.5. Research Methodology
1.6. Information Procurement
- 1.6.1. Purchased Database
- 1.6.2. GVR's Internal Database
- 1.6.3. Secondary Sources
- 1.6.4. Primary research
1.7. Information or Data Analysis
- 1.7.1. Data Analysis Models
1.8. Market Formulation & Validation
1.9. Model Details
- 1.9.1. Commodity Flow Analysis
1.10. List of Secondary Sources
1.11. List of Abbreviations

Chapter 2. Executive Summary

2.1. Market Snapshot
2.2. Type and Test Type Snapshot
2.3. Product and End Use Snapshot
2.4. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

3.1. Market Lineage Outlook
- 3.1.1. Parent Market Outlook
- 3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
  - 3.2.1.1. Presence of research funding programs
  - 3.2.1.2. Presence of favorable government initiatives
  - 3.2.1.3. Growing patient awareness levels
  - 3.2.1.4. Technological innovation in the form of lab automation
- 3.2.2. Market Restraint Analysis
  - 3.2.2.1. Slow diagnostic result turnaround times and lack of skilled healthcare practitioners
3.3. Industry Analysis Tools
- 3.3.1. Porter's Five Forces Analysis
- 3.3.2. PESTEL Analysis

Chapter 4. Type Business Analysis

4.1. Autoimmune Disease Diagnostics Market: Type Movement Analysis
4.2. Systemic Autoimmune Disease Diagnostics
- 4.2.1. Systemic Autoimmune Disease Diagnostics Market, 2018 - 2030 (USD Million)
- 4.2.2. Rheumatoid Arthritis Diagnostics
  - 4.2.2.1. Rheumatoid Arthritis Diagnostics Market, 2018 - 2030 (USD Million)
- 4.2.3. Ankylosing Spondylitis Diagnostics
  - 4.2.3.1. Ankylosing Spondylitis Diagnostics Market, 2018 - 2030 (USD Million)
- 4.2.4. Systemic Lupus Erythematosus (SLE) Diagnostics
  - 4.2.4.1. Systemic Lupus Erythematosus (SLE) Diagnostics Market, 2018 - 2030 (USD Million)
- 4.2.5. Other Systemic Autoimmune Disease Diagnostics
  - 4.2.5.1. Other Systemic Autoimmune Disease Diagnostics Market, 2018 - 2030 (USD Million)
4.3. Localized Disease Diagnostics
- 4.3.1. Localized Disease Diagnostics Market, 2018 - 2030 (USD Million)
- 4.3.2. Multiple sclerosis diagnostics
  - 4.3.2.1. Multiple Sclerosis Diagnostics Market, 2018 - 2030 (USD Million)
- 4.3.3. Type 1 Diabetes Diagnostics
  - 4.3.3.1. Type 1 Diabetes Diagnostics Market, 2018 - 2030 (USD Million)
- 4.3.4. Hashimoto's Thyroiditis Diagnostics
  - 4.3.4.1. Hashimoto's Thyroiditis Diagnostics Market, 2018 - 2030 (USD Million)
- 4.3.5. Idiopathic Thrombocytopenic Purpura (ITP) diagnostics
  - 4.3.5.1. Idiopathic Thrombocytopenic Purpura (ITP) diagnostics Market, 2018 - 2030 (USD Million)
- 4.3.6. Other Localized Autoimmune Disease Diagnostics
  - 4.3.6.1. Other Localized Autoimmune Disease Diagnostics Market, 2018 - 2030 (USD Million)

Chapter 5. Product Business Analysis

5.1. Autoimmune Disease Diagnostics Market: Product Movement Analysis
5.2. Instruments
- 5.2.1. Instruments Market, 2018 - 2030 (USD Million)
5.3. Consumables and Assays
- 5.3.1. Consumables and Assays Market, 2018 - 2030 (USD Million)

Chapter 6. Test Type Business Analysis

6.1. Autoimmune Disease Diagnostics Market: Test Type Movement Analysis
6.2. Antinuclear Antibody Tests
- 6.2.1. Antinuclear Antibody Tests Market, 2018 - 2030 (USD Million)
6.3. Autoantibody Tests
- 6.3.1. Autoantibody Tests Market, 2018 - 2030 (USD Million)
6.4. C-reactive Protein (CRP)
- 6.4.1. C-Reactive Protein (CRP) Market, 2018 - 2030 (USD Million)
6.5. Complete Blood Count (CBC)
- 6.5.1. Complete Blood Count (CBC) Market, 2018 - 2030 (USD Million)
6.6. Urinalysis
- 6.6.1. Urinalysis Market, 2018 - 2030 (USD Million)
6.7. Others
- 6.7.1. Others Market, 2018 - 2030 (USD Million)

Chapter 7. End Use Business Analysis

7.1. Autoimmune Disease Diagnostics Market: End Use Movement Analysis
7.2. Hospitals
- 7.2.1. Hospitals Market, 2018 - 2030 (USD Million)
7.3. Diagnostic Centers
- 7.3.1. Diagnostic Centers Market, 2018 - 2030 (USD Million)
7.4. Others
- 7.4.1. Others Market, 2018 - 2030 (USD Million)

Chapter 8. Regional Business Analysis

8.1. Autoimmune Disease Diagnostics Market Share By Region, 2024 & 2030
8.2. North America
- 8.2.1. SWOT Analysis
- 8.2.2. North America Autoimmune Disease Diagnostics Market, 2018 - 2030 (USD Million)
- 8.2.3. U.S.
  - 8.2.3.1. Key Country Dynamics
  - 8.2.3.2. Target Disease Prevalence
  - 8.2.3.3. Competitive Scenario
  - 8.2.3.4. Regulatory Framework
  - 8.2.3.5. U.S. Autoimmune Disease Diagnostics Market, 2018 - 2030 (USD Million)
- 8.2.4. Canada
  - 8.2.4.1. Key Country Dynamics
  - 8.2.4.2. Target Disease Prevalence
  - 8.2.4.3. Competitive Scenario
  - 8.2.4.4. Regulatory Framework
  - 8.2.4.5. Canada Autoimmune Disease Diagnostics Market, 2018 - 2030 (USD Million)
- 8.2.5. Mexico
  - 8.2.5.1. Key Country Dynamics
  - 8.2.5.2. Target Disease Prevalence
  - 8.2.5.3. Competitive Scenario
  - 8.2.5.4. Regulatory Framework
  - 8.2.5.5. Mexico Autoimmune Disease Diagnostics Market, 2018 - 2030 (USD Million)
8.3. Europe
- 8.3.1. SWOT Analysis
- 8.3.2. Europe Autoimmune Disease Diagnostics Market, 2018 - 2030 (USD Million)
- 8.3.3. UK
  - 8.3.3.1. Key Country Dynamics
  - 8.3.3.2. Target Disease Prevalence
  - 8.3.3.3. Competitive Scenario
  - 8.3.3.4. Regulatory Framework
  - 8.3.3.5. UK Autoimmune Disease Diagnostics Market, 2018 - 2030 (USD Million)
- 8.3.4. Germany
  - 8.3.4.1. Key Country Dynamics
  - 8.3.4.2. Target Disease Prevalence
  - 8.3.4.3. Competitive Scenario
  - 8.3.4.4. Regulatory Framework
  - 8.3.4.5. Germany Autoimmune Disease Diagnostics Market, 2018 - 2030 (USD Million)
- 8.3.5. France
  - 8.3.5.1. Key Country Dynamics
  - 8.3.5.2. Target Disease Prevalence
  - 8.3.5.3. Competitive Scenario
  - 8.3.5.4. Regulatory Framework
  - 8.3.5.5. France Autoimmune Disease Diagnostics Market, 2018 - 2030 (USD Million)
- 8.3.6. Italy
  - 8.3.6.1. Key Country Dynamics
  - 8.3.6.2. Target Disease Prevalence
  - 8.3.6.3. Competitive Scenario
  - 8.3.6.4. Regulatory Framework
  - 8.3.6.5. Italy Autoimmune Disease Diagnostics Market, 2018 - 2030 (USD Million)
- 8.3.7. Spain
  - 8.3.7.1. Key Country Dynamics
  - 8.3.7.2. Target Disease Prevalence
  - 8.3.7.3. Competitive Scenario
  - 8.3.7.4. Regulatory Framework
  - 8.3.7.5. Spain Autoimmune Disease Diagnostics Market, 2018 - 2030 (USD Million)
- 8.3.8. UK
  - 8.3.8.1. Key Country Dynamics
  - 8.3.8.2. Target Disease Prevalence
  - 8.3.8.3. Competitive Scenario
  - 8.3.8.4. Regulatory Framework
  - 8.3.8.5. UK Autoimmune Disease Diagnostics Market, 2018 - 2030 (USD Million)
- 8.3.9. Sweden
  - 8.3.9.1. Key Country Dynamics
  - 8.3.9.2. Target Disease Prevalence
  - 8.3.9.3. Competitive Scenario
  - 8.3.9.4. Regulatory Framework
  - 8.3.9.5. Sweden Autoimmune Disease Diagnostics Market, 2018 - 2030 (USD Million)
- 8.3.10. Norway
  - 8.3.10.1. Key Country Dynamics
  - 8.3.10.2. Target Disease Prevalence
  - 8.3.10.3. Competitive Scenario
  - 8.3.10.4. Regulatory Framework
  - 8.3.10.5. Norway Autoimmune Disease Diagnostics Market, 2018 - 2030 (USD Million)
- 8.3.11. Denmark
  - 8.3.11.1. Key Country Dynamics
  - 8.3.11.2. Target Disease Prevalence
  - 8.3.11.3. Competitive Scenario
  - 8.3.11.4. Regulatory Framework
  - 8.3.11.5. Denmark Autoimmune Disease Diagnostics Market, 2018 - 2030 (USD Million)
8.4. Asia Pacific
- 8.4.1. SWOT Analysis
- 8.4.2. Asia Pacific Autoimmune Disease Diagnostics Market, 2018 - 2030 (USD Million)
- 8.4.3. Japan
  - 8.4.3.1. Key Country Dynamics
  - 8.4.3.2. Target Disease Prevalence
  - 8.4.3.3. Competitive Scenario
  - 8.4.3.4. Regulatory Framework
  - 8.4.3.5. Japan Autoimmune Disease Diagnostics Market, 2018 - 2030 (USD Million)
- 8.4.4. China
  - 8.4.4.1. Key Country Dynamics
  - 8.4.4.2. Target Disease Prevalence
  - 8.4.4.3. Competitive Scenario
  - 8.4.4.4. Regulatory Framework
  - 8.4.4.5. China Autoimmune Disease Diagnostics Market, 2018 - 2030 (USD Million)
- 8.4.5. India
  - 8.4.5.1. Key Country Dynamics
  - 8.4.5.2. Target Disease Prevalence
  - 8.4.5.3. Competitive Scenario
  - 8.4.5.4. Regulatory Framework
  - 8.4.5.5. India Autoimmune Disease Diagnostics Market, 2018 - 2030 (USD Million)
- 8.4.6. Australia
  - 8.4.6.1. Key Country Dynamics
  - 8.4.6.2. Target Disease Prevalence
  - 8.4.6.3. Competitive Scenario
  - 8.4.6.4. Regulatory Framework
  - 8.4.6.5. Australia Autoimmune Disease Diagnostics Market, 2018 - 2030 (USD Million)
- 8.4.7. Thailand
  - 8.4.7.1. Key Country Dynamics
  - 8.4.7.2. Target Disease Prevalence
  - 8.4.7.3. Competitive Scenario
  - 8.4.7.4. Regulatory Framework
  - 8.4.7.5. Thailand Autoimmune Disease Diagnostics Market, 2018 - 2030 (USD Million)
- 8.4.8. South Korea
  - 8.4.8.1. Key Country Dynamics
  - 8.4.8.2. Target Disease Prevalence
  - 8.4.8.3. Competitive Scenario
  - 8.4.8.4. Regulatory Framework
  - 8.4.8.5. South Korea Autoimmune Disease Diagnostics Market, 2018 - 2030 (USD Million)
8.5. Latin America
- 8.5.1. SWOT Analysis
- 8.5.2. Latin America Autoimmune Disease Diagnostics Market, 2018 - 2030 (USD Million)
- 8.5.3. Brazil
  - 8.5.3.1. Key Country Dynamics
  - 8.5.3.2. Target Disease Prevalence
  - 8.5.3.3. Competitive Scenario
  - 8.5.3.4. Regulatory Framework
  - 8.5.3.5. Brazil Autoimmune Disease Diagnostics Market, 2018 - 2030 (USD Million)
- 8.5.4. Argentina
  - 8.5.4.1. Key Country Dynamics
  - 8.5.4.2. Target Disease Prevalence
  - 8.5.4.3. Competitive Scenario
  - 8.5.4.4. Regulatory Framework
  - 8.5.4.5. Argentina Autoimmune Disease Diagnostics Market, 2018 - 2030 (USD Million)
8.6. MEA
- 8.6.1. SWOT Analysis
- 8.6.2. MEA Autoimmune Disease Diagnostics Market, 2018 - 2030 (USD Million)
- 8.6.3. South Africa
  - 8.6.3.1. Key Country Dynamics
  - 8.6.3.2. Target Disease Prevalence
  - 8.6.3.3. Competitive Scenario
  - 8.6.3.4. Regulatory Framework
  - 8.6.3.5. South Africa Autoimmune Disease Diagnostics Market, 2018 - 2030 (USD Million)
- 8.6.4. Saudi Arabia
  - 8.6.4.1. Key Country Dynamics
  - 8.6.4.2. Target Disease Prevalence
  - 8.6.4.3. Competitive Scenario
  - 8.6.4.4. Regulatory Framework
  - 8.6.4.5. Saudi Arabia Autoimmune Disease Diagnostics Market, 2018 - 2030 (USD Million)
- 8.6.5. UAE
  - 8.6.5.1. Key Country Dynamics
  - 8.6.5.2. Target Disease Prevalence
  - 8.6.5.3. Competitive Scenario
  - 8.6.5.4. Regulatory Framework
  - 8.6.5.5. UAE Autoimmune Disease Diagnostics Market, 2018 - 2030 (USD Million)
- 8.6.6. Kuwait
  - 8.6.6.1. Key Country Dynamics
  - 8.6.6.2. Target Disease Prevalence
  - 8.6.6.3. Competitive Scenario
  - 8.6.6.4. Regulatory Framework
  - 8.6.6.5. Kuwait Autoimmune Disease Diagnostics Market, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

9.1. Company Categorization
9.2. Strategy Mapping
9.3. Company Market Share Analysis, 2024
9.4. Company Profiles/Listing
- 9.4.1. F. Hoffmann-La Roche Ltd
  - 9.4.1.1. Overview
  - 9.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
  - 9.4.1.3. Product Benchmarking
  - 9.4.1.4. Strategic Initiatives
- 9.4.2. Siemens Healthcare Private Limited
  - 9.4.2.1. Overview
  - 9.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
  - 9.4.2.3. Product Benchmarking
  - 9.4.2.4. Strategic Initiatives
- 9.4.3. Abbott
  - 9.4.3.1. Overview
  - 9.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
  - 9.4.3.3. Product Benchmarking
  - 9.4.3.4. Strategic Initiatives
- 9.4.4. Beckman Coulter, Inc.
  - 9.4.4.1. Overview
  - 9.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
  - 9.4.4.3. Product Benchmarking
  - 9.4.4.4. Strategic Initiatives
- 9.4.5. Danaher Corporation
  - 9.4.5.1. Overview
  - 9.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
  - 9.4.5.3. Product Benchmarking
  - 9.4.5.4. Strategic Initiatives
- 9.4.6. Quest Diagnostics
  - 9.4.6.1. Overview
  - 9.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
  - 9.4.6.3. Product Benchmarking
  - 9.4.6.4. Strategic Initiatives
- 9.4.7. EUROIMMUN Medizinische Labordiagnostika AG
  - 9.4.7.1. Overview
  - 9.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
  - 9.4.7.3. Product Benchmarking
  - 9.4.7.4. Strategic Initiatives
- 9.4.8. Nova Diagnostics Pte Ltd.
  - 9.4.8.1. Overview
  - 9.4.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
  - 9.4.8.3. Product Benchmarking
  - 9.4.8.4. Strategic Initiatives
- 9.4.9. BIOMERIEUX
  - 9.4.9.1. Overview
  - 9.4.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
  - 9.4.9.3. Product Benchmarking
  - 9.4.9.4. Strategic Initiatives
- 9.4.10. Hemagen Diagnostics, Inc.
  - 9.4.10.1. Overview
  - 9.4.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
  - 9.4.10.3. Product Benchmarking
  - 9.4.10.4. Strategic Initiatives